L-Prolinamide, N-(19-Carboxy-1-Oxononadecyl)-L-?-Glutamyl-L-Arginyl-L-?-Aspartylglycyl-L-Threonyl-L-Alanyl-L-Threonyl-L-Lysyl-L-Alanyl-L-Threonyl-L-?-Glutamyl-L-Arginyl-L-Leucyl-L-Alanyl-5-Carboxy-L-Norvalyl-L-Phenylalanyl-L-Leucyl-L-Glutaminyl-L-Arginyl-L-Seryl-L-Seryl-L-Phenylalanyl-N-Methylglycyl-L-Alanyl-N-Methyl-L-Isoleucyl-L-Leucyl-L-Seryl-L-Seryl-L-Threonyl-L-?-Glutamyl-L-Valylglycyl-L-Seryl-L-Asparaginyl-L-Threonyl-4-Hydroxy-, (3?8)-Lactam, (4R)-
Obesity Disorder
Explore 465 assets in Obesity Disorder →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Hoffmann-La Roche
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07589686CT.gov A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight | — | Not Yet Recruiting | — | — | — |
NCT07338214CT.gov Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations | — | Completed | — | — | — |
NCT06926842CT.gov Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) | — | Active Not Recruiting | — | — | — |
NCT06662539CT.gov Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities | — | Completed | — | — | — |
NCT05613387CT.gov A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| L-Prolinamide, N-(19-Carboxy-1-Oxononadecyl)-L-?-Glutamyl-L-Arginyl-L-?-Aspartylglycyl-L-Threonyl-L-Alanyl-L-Threonyl-L-Lysyl-L-Alanyl-L-Threonyl-L-?-Glutamyl-L-Arginyl-L-Leucyl-L-Alanyl-5-Carboxy-L-Norvalyl-L-Phenylalanyl-L-Leucyl-L-Glutaminyl-L-Arginyl-L-Seryl-L-Seryl-L-Phenylalanyl-N-Methylglycyl-L-Alanyl-N-Methyl-L-Isoleucyl-L-Leucyl-L-Seryl-L-Seryl-L-Threonyl-L-?-Glutamyl-L-Valylglycyl-L-Seryl-L-Asparaginyl-L-Threonyl-4-Hydroxy-, (3?8)-Lactam, (4R)- (this asset) | Hoffmann-La Roche | P2 | CCC · 53 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for L-Prolinamide, N-(19-Carboxy-1-Oxononadecyl)-L-?-Glutamyl-L-Arginyl-L-?-Aspartylglycyl-L-Threonyl-L-Alanyl-L-Threonyl-L-Lysyl-L-Alanyl-L-Threonyl-L-?-Glutamyl-L-Arginyl-L-Leucyl-L-Alanyl-5-Carboxy-L-Norvalyl-L-Phenylalanyl-L-Leucyl-L-Glutaminyl-L-Arginyl-L-Seryl-L-Seryl-L-Phenylalanyl-N-Methylglycyl-L-Alanyl-N-Methyl-L-Isoleucyl-L-Leucyl-L-Seryl-L-Seryl-L-Threonyl-L-?-Glutamyl-L-Valylglycyl-L-Seryl-L-Asparaginyl-L-Threonyl-4-Hydroxy-, (3?8)-Lactam, (4R)-
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Type 2 Diabetes Mellitus | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. L-Prolinamide, N-(19-Carboxy-1-Oxononadecyl)-L-?-Glutamyl-L-Arginyl-L-?-Aspartylglycyl-L-Threonyl-L-Alanyl-L-Threonyl-L-Lysyl-L-Alanyl-L-Threonyl-L-?-Glutamyl-L-Arginyl-L-Leucyl-L-Alanyl-5-Carboxy-L-Norvalyl-L-Phenylalanyl-L-Leucyl-L-Glutaminyl-L-Arginyl-L-Seryl-L-Seryl-L-Phenylalanyl-N-Methylglycyl-L-Alanyl-N-Methyl-L-Isoleucyl-L-Leucyl-L-Seryl-L-Seryl-L-Threonyl-L-?-Glutamyl-L-Valylglycyl-L-Seryl-L-Asparaginyl-L-Threonyl-4-Hydroxy-, (3?8)-Lactam, (4R)- in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/l-prolinamide-n-19-carboxy-1-oxononadecyl-l-glutamyl-l-arginyl-l-aspartylglycyl-l-threonyl-l-alanyl-l-threonyl-l-lysyl-l-alanyl-l-threonyl-l-glutamyl-l-arginyl-l-leucyl-l-alanyl-5-carboxy-l-norvalyl-l-phenylalanyl-l-leucyl-l-glutaminyl-l-arginyl-l-seryl-l-seryl-l-phenylalanyl-n-methylglycyl-l-alanyl-n-methyl-l-isoleucyl-l-leucyl-l-seryl-l-seryl-l-threonyl-l-glutamyl-l-valylglycyl-l-seryl-l-asparaginyl-l-threonyl-4-hydroxy-38-lactam-4r-obesity-disorder-35027
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →